Notice of Results

Avacta Group PLC

23 April 2024

 

23 April 2024

Avacta Group plc

("Avacta" or the "Company" and, together with its subsidiary undertakings, the "Group")

Notice of Results

Investor Presentation via Investor Meet Company

Avacta Group plc (AIM: AVCT), a life sciences company developing innovative, targeted oncology drugs and powerful diagnostics, will announce its audited preliminary results for year ended 31^st December 2023 ("FY23") on 30^th April 2024.

Alastair Smith, Chief Executive Officer; Tony Gardiner, Chief Financial Officer; and Christina Coughlin MD, PhD, Head of Research and Development, will also deliver a live presentation via Investor Meet Company at 12:30 BST on the day.

The presentation is open to all existing and potential shareholders.

Investors can sign up to Investor Meet Company for free and add to meet AVACTA GROUP PLC via:

https://www.investormeetcompany.com/avacta-group-plc/register-investor. Investors who already follow Avacta on the Investor Meet Company platform will automatically be invited.

Questions can be submitted pre-event via the Investor Meet Company dashboard up until 29^th April 09:00 BST, or at any time during the live presentation.

The Company will also post the results presentation on its website at the following page: https://avacta.com/investors/investor-resources/

-Ends-

For further information from Avacta Group plc, please contact:

Avacta Group plc Alastair Smith, Chief Executive Officer Tony Gardiner, Chief Financial Officer Michael Vinegrad, Group Communications Director	Tel: [phone] www.avacta.com
Stifel Nicolaus Europe Limited (Nomad and Joint Broker) Nicholas Moore / Nick Adams / Samira Essebiyea / Nick Harland / Ben Good	Tel: [phone] www.stifel.com
Peel Hunt (Joint Broker) James Steel / Chris Golden / Patrick Birkholm	Tel: [phone] www.peelhunt.com
ICR Consilium (Media and IR) Mary-Jane Elliott / Jessica Hodgson / Sukaina Virji	[e-mail]

About Avacta Group plc - https://www.avacta.com

Avacta Group is a UK-based life sciences company focused on improving healthcare outcomes through targeted cancer treatments and diagnostics.

Avacta has two divisions focused on therapeutics and diagnostics.

Avacta Therapeutics: a clinical stage oncology biotech division harnessing proprietary therapeutic platforms to develop novel, highly targeted cancer drugs.

Avacta Diagnostics: focused on supporting healthcare professionals and broadening access to diagnostics.

Avacta has two proprietary platforms, pre|CISION™ and Affimer^®.

The pre|CISION™ platform is a highly specific substrate for fibroblast activation protein (FAP) which is upregulated in most solid tumours compared with healthy tissues. The pre|CISION™ platform harnesses this tumour specific protease to activate pre|CISION™ peptide drug conjugates and pre|CISION™ antibody/Affimer® drug conjugates in the tumour microenvironment, reducing systemic exposure and toxicity, allowing dosing to be optimised to deliver the best outcomes for patients.

The lead pre|CISION™ programme AVA6000, a peptide drug conjugate form of doxorubicin, is in Phase 1 studies. It has shown a dramatic improvement in safety and tolerability in clinical trials to date compared with standard doxorubicin and preliminary signs of clinical activity in multiple patients.

To register for news alerts by email go to https://avacta.com/investors/investor-news-email-alerts/

 

END